Biogen Reports Phase 3 extension Data for Savolitinib in Systemic mastocytosis

Biogen today announced Phase 3 extension results for Savolitinib in patients with Systemic mastocytosis. The study demonstrated that Savolitinib improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Systemic mastocytosis and support the continued development of Savolitinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Savolitinib was consistent with previous observations, with no new safety signals identified.